A B S T R A C T Serum from a patient with the CREST Syndrome and systemic lupus erythematosus contained an IgM antibody that reacted at dilutions up to 1:800 with a fibrous cytoplasmic network in several epithelioid and fibroblastic cell lines. The antibody was shown by immunofluorescence microscopy to label a specific subset of cytoskeletal polymers, the intermediate filaments. The reactive antigen from this biochemically heterogeneous group of filaments was established as the 58,000-mol wt protein, vimentin: (a) the patient's serum reacts with a range of cell lines that contain intermediate filaments composed of vimentin, but not with cells whose intermediate filaments are composed of different protein subunits; (b) in PTK2 epithelioid cells the serum reacts with the class of filaments that coils around the nucleus after colchicine treatment (vimentin) and not with the filaments that remain dispersed after colchicine (prekeratin); and (c) the component of reactive cells that combines with the serum is shown by immunoelectrophoresis to be a 58,000-mol wt protein antigen. A similar antibody that binds intermediate filaments of PTK2 cells was encountered at lower titer in some sera from other patients with connective tissue diseases and in control sera. Previous routine antinuclear antibody assays using mouse liver or commercially prepared HEp-2 cells have failed to reveal anticytoskeletal an- Antibodies. Antitubulin and antiactin antibodies were described elsewhere (9) . Dr. R. 0. Hynes kindly provided rabbit antirat fibroblast 58,000-mol wt protein (vimentin) antibody (10 
RESULTS
Observation and immunological characterization of an antibody to INFIL. HEp-2 cells provided in ANA assay kits by Antibodies, Inc. showed indistinct cytoplasmic fluorescence and striking nuclear and centromere fluorescence after incubation with M.S. serum (1:20) and fluorescein anti-human immunoglobulins (Fig. 1A) . At dilutions of M.S. serum >1:160, cytoplasmic fluorescence was absent and the centromere pattern was prominant (Fig. IB) . In contrast, freshly grown HEp-2 and PTK2 cells treated with M.S. serum and fluorescein anti-human Igs revealed an intricate, wavy, three-dimensional filamentous network that showed an increased density around the nucleus and spread throughout the cytoplasm (Fig. 1C) . These filaments formed a cage or basket around the chromosomes of mitotic cells. Mitotic spindles were unstained. Nuclear fluorescence was typically diffuse or peripheral.
The INFIL pattern observed in PTK2 cells labeled with rabbit anti-rat 58,000-mol wt (vimentin) antibody was closely similar to the cytoplasmic pattern due to M.S. serum. Entirely different patterns were obtained in PTK2 labeled with goat anti-bovine brain tubulin (where interphase cells contained microtubules focused upon centrioles and mitotic cells showed intensely fluorescent mitotic spindles) and with human anti-actin (where parallel microfilament bundles were labeled). INFIL (2, 3, 6, 8) . In the case of primary mouse skin cultures fibroblasts (primarily vimentin INFIL). All cells ex- (Fig. 1D) unreactive keratinocytes (reported to contain amined bound M.S. antibodies to nuclear antigens, inonly prekeratin INFIL) were surrounded by reactive dicating adequate antibody penetration. treatment (1 ,uM; 12 h) causes the vimentin INFIL of PTK2 cells to coil around the nucleus, whereas the prekeratin INFIL remain dispersed in the cytoplasm. The filaments recognized by M.S. serum were coiled into a juxtanuclear mass after colchicine treatment (Fig. 1E) .
Immunoelectrophoresis. SDS-gel electrophoretograms of PTK2 and CHO cells were examined for proteins that bound M.S. serum and could be visualized with fluorescein anti-IgM or anti-IgM '251-protein A.
M.S. serum recognized a single protein in Triton extracts of both PTK2 and CHO cells. This band was coincident with vimentin, the major 58,000-mol wt protein of CHO extracts and one of several major proteins in PTK2 extracts (Fig. 2) .
Other sera. Antibodies to INFIL have been noted in sera from 6 (17) and cancer (18) . Antimitotic (vimentin) that coils around the nucleus following colchicine treatment and not with the class that remains dispersed after colchicine (prekeratin); and (c) reaction of M.S. antibody with a 58,000-mol wt protein (vimentin) on SDS gels of both PTK2 and CHO cell extracts.
It remains to be determined if antibodies to INFIL proteins contribute to the loss of cell functions or other aspects of the pathogenesis of connective tissue disease. Whether or not such antibodies are of clinical importance, they are useful tools to probe the structure and function of the mammalian cytoskeleton.
